Live Ventures Incorporated Common Stock (LIVE)

FairStock Score: 54/100 — MIXED

Key Financials

Strengths

• Generates $22 million in annual free cash flow (52.7% yield on market cap)
• High return on equity of 26.3% demonstrating efficient capital deployment

Concerns

• High leverage at 2.35x debt-to-equity increases financial risk and interest expense burden
• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
• Revenue declining at 2.7% year-over-year signals potential demand weakness or market share loss
• Altman Z-Score of 0.7 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Live Ventures Incorporated Common Stock is a micro-cap consumer cyclical company valued at $43 million. Revenue stands at $442 million, though the company is currently unprofitable. From a quality standpoint, Live shows distressed Altman Z-Score of 0.7 warrants caution and strong 26% ROE. On valuation, the stock is deeply undervalued on a P/E basis at 2.9x, with offers a 76% margin of safety vs Graham Number of $58. Growth dynamics show revenue growing at -2.7% and profit growth of -113.0%. Our composite FairStock Score of 54/100 reflects mixed fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.

Bull Case

The market underappreciates Live's consistent 26% ROE at just 3x earnings—a re-rating toward sector peers could unlock 30-50% upside. With $22 million in annual free cash flow (52.7% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer